Astellas Pharma ( OTCPK:ALPMY ) signed an agreement with YASKAWA Electric to create an innovative cell therapy ecosystem through the integration of pharmaceutical and robotics technologies. The complexity of product manufacturing is a significant challenge to commercializing cell therapy. The companies will begin discussions to potentially develop a platform that may seamlessly link early-stage research to commercialization, utilizing the state-of-the-art Maholo robot to manufacture high-quality products and shorten the R&D period of cell therapy.
Astellas said the impact of this agreement on its financial results for the FY 2025 is expected to be minor. More on Astellas Pharma Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.
67B; initiates FY24 guidance Pfizer, Astellas first-line bladder cancer therapy accepted for review in China Seeking Alpha’s Quant Rating on Astellas Pharma ADR Historical earnings data for Astellas Pharma ADR.
